Montesanti R - Search Results

1

Impaired flow-mediated dilation and risk of restenosis in patients undergoing coronary stent implantation.

Patti G, Pasceri V, Melfi R, Goffredo C, Chello M, D'Ambrosio A, Montesanti R, Di Sciascio G. Patti G, et al. Among authors: montesanti r. Circulation. 2005 Jan 4;111(1):70-5. doi: 10.1161/01.CIR.0000151308.06673.D2. Circulation. 2005. PMID: 15630038

2

[Platelet glycoprotein IIB-IIIA receptor inhibitors in patients with ischemic heart disease].

Patti G, Fossati C, Manzoli A, D'Ambrosio A, Abbate A, Montesanti R, Di Sciascio G. Patti G, et al. Among authors: montesanti r. Clin Ter. 2000 Jul-Aug;151(4):301-6. Clin Ter. 2000. PMID: 11107681 Review. Italian.

3

[Statins: from hypocholesteremic drugs to antiatherogenic agents].

Manzoli A, Patti G, D'Ambrosio A, Montesanti R, Calabrese V, Abbate A, Gioia G, Di Sciascio G. Manzoli A, et al. Among authors: montesanti r. Clin Ter. 2001 Sep-Oct;152(5):307-13. Clin Ter. 2001. PMID: 11794851 Review. Italian.

4

[Depressive syndrome and ischemic cardiopathy].

Araquistain JM, Montesanti R. Araquistain JM, et al. Among authors: montesanti r. Clin Ter. 2003 Jul-Aug;154(4):251-4. Clin Ter. 2003. PMID: 14618942 Review. Italian.

5

Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD.

Oliveri RL, Annesi G, Zappia M, Civitelli D, Montesanti R, Branca D, Nicoletti G, Spadafora P, Pasqua AA, Cittadella R, Andreoli V, Gambardella A, Aguglia U, Quattrone A. Oliveri RL, et al. Among authors: montesanti r. Neurology. 1999 Oct 22;53(7):1425-30. doi: 10.1212/wnl.53.7.1425. Neurology. 1999. PMID: 10534246

6

The subacute levodopa test for evaluating long-duration response in Parkinson's disease.

Quattrone A, Zappia M, Aguglia U, Branca D, Colao R, Montesanti R, Nicoletti G, Palmieri A, Parlato G, Rizzo M. Quattrone A, et al. Among authors: montesanti r. Ann Neurol. 1995 Sep;38(3):389-95. doi: 10.1002/ana.410380308. Ann Neurol. 1995. PMID: 7668824

7

Usefulness of movement time in the assessment of Parkinson's disease.

Zappia M, Montesanti R, Colao R, Quattrone A. Zappia M, et al. Among authors: montesanti r. J Neurol. 1994 Aug;241(9):543-50. doi: 10.1007/BF00873517. J Neurol. 1994. PMID: 7799003 Clinical Trial.

8

Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease.

Zappia M, Montesanti R, Colao R, Branca D, Nicoletti G, Aguglia U, Quattrone A. Zappia M, et al. Among authors: montesanti r. Mov Disord. 1997 Jan;12(1):103-6. doi: 10.1002/mds.870120118. Mov Disord. 1997. PMID: 8990062

9

Long-duration response to levodopa influences the pharmacodynamics of short-duration response in Parkinson's disease.

Zappia M, Colao R, Montesanti R, Rizzo M, Aguglia U, Gambardella A, Oliveri RL, Quattrone A. Zappia M, et al. Among authors: montesanti r. Ann Neurol. 1997 Aug;42(2):245-8. doi: 10.1002/ana.410420217. Ann Neurol. 1997. PMID: 9266736

10

CAG repeat length and clinical features in three Italian families with spinocerebellar ataxia type 2 (SCA2): early impairment of Wisconsin Card Sorting Test and saccade velocity.

Gambardella A, Annesi G, Bono F, Spadafora P, Valentino P, Pasqua AA, Mazzei R, Montesanti R, Conforti FL, Oliveri RL, Zappia M, Aguglia U, Quattrone A. Gambardella A, et al. Among authors: montesanti r. J Neurol. 1998 Oct;245(10):647-52. doi: 10.1007/s004150050261. J Neurol. 1998. PMID: 9776463

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

20 results

Search Page